Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

sTREM2

Method of Measurement (Pre-analytical Tools)
CSF
Biomarker Measured
Neuronal damage
Use
Diagnostic
Monitoring
Stage of Development
Clinical trials
Active vs Completed Trials
Completed
Aim/Results

CSF sTREM2 levels are increased in the early symptomatic phase of AD, probably reflecting a corresponding change of the microglia activation status in response to neuronal degeneration. Moreover, increased CSF sTREM2 levels were associated with higher CSF total tau and phospho‐tau181P, which are markers of neuronal degeneration and tau pathology.

What is Required from Patients

Invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage

What is Required from the Health System

physican who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, or western blot)

Sponsor

German Center for Neurodegenerative Diseases (DZNE) Munich; Ludwig-Maximilians-Universität München, Munich; Munich Cluster for Systems Neurology (SyNergy); Washington University School of Medicine; UCL Institute of Neurology, Queen Square, London; Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg

  1. Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., ... & Mills, K. (2016). Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease. Molecular neurodegeneration, 11(1), 3. https://www.ncbi.nlm.nih.gov/pubmed/26754172

  2. Suárez-Calvet, M., Caballero, M. Á. A., Kleinberger, G., Bateman, R. J., Fagan, A. M., Morris, J. C., ... & Dominantly Inherited Alzheimer Network. (2016). Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury. Science translational medicine, 8(369), 369ra178-369ra178. https://www.ncbi.nlm.nih.gov/pubmed/27974666

  3. Suárez‐Calvet, M., Kleinberger, G., Caballero, M. Á. A., Brendel, M., Rominger, A., Alcolea, D., ... & Sánchez‐Valle, R. (2016). sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers. EMBO molecular medicine, e201506123. https://www.ncbi.nlm.nih.gov/pubmed/26941262